Blood test predicts immunotherapy benefit early among patients with advanced lung cancer

Researchers astatine the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy determined that liquid biopsy—a humor trial that detects circulating tumor DNA (ctDNA)—can predict, wrong a fewer weeks, whether patients with precocious non-small compartment lung crab are benefiting from immunotherapy. This uncovering has the imaginable to facilitate aboriginal attraction decisions, allowing physicians to alteration therapies improbable to payment patients months sooner than is presently imaginable with modular imaging.